الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 109 |  |  |
| | | from | 109 | | |
Abstract
Background: SARS-CoV-2 is a novel coronavirus that causes COVID-19. On March 11, 2020, the SARS-CoV-2 virus spread worldwide. Infected patients experience a wide spectrum of respiratory, neurologic, gastrointestinal, musculoskeletal, and vascular symptoms, which normally last no longer than 2-3 weeks. There have been several emerging reports of people with COVID-19 who have continued to experience symptoms, also known as post-COVID syndrome (PCS) or long COVID like fatigue, myalgia, arthralgia, decreased physical and cognitive performance, headaches and other symptoms that interfere with daily activities.
Objective: to screen for musculoskeletal symptoms in a random sample of post-COVID survivors and if there is a relationship between these symptoms and the past infection.
Patients and methods: 102 post-covid survivors were included and subdivided into two groups: the hospitalised group (36) and the home-treated group (66). All of them underwent detailed history-taking and complete general, neurological and locomotor examination. Sensory and motor conduction studies, as well as an electromyography study, were conducted as part of the electro-diagnostic workup and patient evaluation was achieved utilizing the Chalder Fatigue Questionnaire (CFQ 14) and the 2016 Revised ACR Fibromyalgia Diagnostic Criteria. Furthermore, Sera of our survivors were examined regarding rheumatoid factor, ANA, anticardiolipin IgG, ANCA and Anti-CCP antibodies.
Results: myalgia, arthralgia and arthritis were each noted by 36.3%, 58.8% and 17.6 % of our post-covid survivors, respectively. NCS abnormalities were seen in 31.4% of the studied population (7.8% sensory, 16.7% motor and 6.9% combined motor and sensory abnormalities). 33.3% were determined to have chronic fatigue using the Chalder Fatigue Questionnaire (CFQ14), whose scores range from 0 to 33 using likert scale; a higher score denotes more severe fatigue. Meanwhile, 12.7% met the 2016 Revision of the American College of Rheumatology Fibromyalgia Diagnostic Criteria. Moreover,two cases were recently diagnosed as SLE shortly after COVID infection. In addition, the anti-CCP antibody was positive in two patients, but no patient in our study sample had a positive RF. The ANA was positive in 17.6% of cases (which was more common in hospitalized patients and showed a positive correlation with arthritis), while ANCA and Anti-cardiolipin antibodies were positive in 5.9% and 15.7%, respectively.